Fig. 4From: Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfaHigh C3M/PRO-C3 ratio was predictive of treatment-specific OS in Stage 2 of HALO 109-202 using Stage 1 cut-offs. C3M/PRO-C3 ratio subgroups defined by a median cut-off derived from Stage 1 and b ROC cut-off derived from Stage 1Back to article page